<DOC>
	<DOCNO>NCT02675998</DOCNO>
	<brief_summary>This phase 3 , 8-week , randomize , double-blind , parallel group , multi-center study 4-week , placebo-controlled , randomized withdrawal period evaluate efficacy , safety tolerability Tenapanor treat hyperphosphatemia end-stage renal disease patient hemodialysis ( ESRD-HD ) . Subjects qualify randomize study either receive 3 mg BID , 10 mg BID , titration regimen tenapanor .</brief_summary>
	<brief_title>An 8-Week Study Evaluate Tenapanor Treatment Hyperphosphatemia End-Stage Renal Disease Patients Hemodialysis ( ESRD-HD )</brief_title>
	<detailed_description>The study consist screen visit , wash period 3 week , exist phosphate lower medication withheld , 8-week treatment period , group receive tenapanor , 4-week placebo-controlled , randomized withdrawal period , patient re-randomized 1:1 either remain current tenapanor treatment placebo . Depending increase serum phosphate level , subject randomize 1,2 , 3 week take phosphate lowering medication .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>18 80 year old Females must nonpregnant , nonlactating , either postmenopausal least 12 month , documentation irreversible surgical sterilization , confirm use one acceptable contraceptive method . Males must agree avoid father child agree use appropriate method contraception Chronic maintenance hemodialysis 3x/week least 3 month Kt/V ≥ 1.3 recent measurement prior screen Prescribed take least 3 dos phosphate binder per day Serum phosphate level 4.0 7.0 mg/dL ( inclusive ) screen For randomization study , 1 week washout phosphate binder , subject must serum phosphate level least 9 mg/dL 10 mg/dL increase least 1.5 mg/dL versus prewash value For randomization study , 2 3 week washout phosphate binder , subject must serum phosphate level least 6 mg/dL 10 mg/dL increase least 1.5 mg/dL versus prewash value Severe hyperphosphatemia define &gt; 10 mg/dL Phosphatebinders time point clinical routine monitoring 3 preceding month screen Serum parathyroid hormone &gt; 1200 pg/mL Persistent metabolic acidosis define serum carbon dioxide &lt; 18 mmol/L two consecutive measurement screen washout period Clinical sign hypovolemia randomization History inflammatory bowel disease ( IBD ) diarrhea predominant irritable bowel syndrome ( IBSD ) Scheduled live donor kidney transplant , change peritoneal dialysis , home HD plan relocate another center study period Diarrhea loose stool week randomization define BSFS ≥ 6 frequency ≥ 3 2 day Any evidence treatment malignancy within one year , exclude nonmelanomatous malignancy skin Positive serology evidence significant hepatic impairment WBC elevation accord Investigator Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>